Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

Brief Title

Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

Official Title

Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

Brief Summary

      For many years, researchers and doctors have studied different kinds of treatments to improve
      the survival of men with testicular cancer. However, recent research has shown that many
      years later, men who had testicular cancer appear to be at higher risk for developing heart
      disease (heart attack or heart failure), especially if they received chemotherapy. Since
      these studies were done many years after men received treatment, there was no way to know if
      other factors contributed to the health problems they experienced. This study is being done
      because it would be helpful to study heart function and cardiovascular disease risk factors
      of men who have been diagnosed with testicular cancer, before and after they receive
      chemotherapy treatment compared to men who receive treatment with surgery alone.
    

Detailed Description

      The aim of this pilot study is to examine global and regional LV systolic and diastolic
      function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently
      diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.
    


Study Type

Observational




Condition

Testicular Cancer


Study Arms / Comparison Groups

 1
Description:  Testicular cancer patients who have received surgery and are scheduled for surveillance

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

30

Start Date

September 2008

Completion Date

July 2012

Primary Completion Date

May 2011

Eligibility Criteria

        Inclusion Criteria:

          -  surgery and surveillance

          -  surgery and multi-cycle chemotherapy

          -  both good and intermediate prognosis seminoma and non-seminomatous germ cell
             testicular tumors

          -  Karnofsky performance index > 70%

          -  no contraindications to cardiopulmonary testing

        Exclusion Criteria:

          -  documented cardiovascular disease or evidence of myocardial ischemia on the
             incremental exercise (VO2peak) test.
      

Gender

Male

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Mark Haykowsky, PhD, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT00705094

Organization ID

GU-24167


Responsible Party

Sponsor

Study Sponsor

AHS Cancer Control Alberta


Study Sponsor

Mark Haykowsky, PhD, Principal Investigator, University of Alberta


Verification Date

September 2014